** Shares of drug developer Amylyx Pharmaceuticals AMLX.O rise 1.9% to $5.45 premarket
** Co announces late-stage trial design for its experimental GLP-1 antagonist treatment, avexitide, to treat a type of low blood sugar called post-bariatric hypoglycemia $(PBH)$
** PBH is a condition that affects approximately 8% of people who have undergone bariatric surgery- AMLX
** The trial is designed to evaluate FDA-agreed upon primary goal of reduction in hypoglycemia or low blood sugar events- AMLX
** Co expects to dose the first study participant in the first quarter of 2025, followed by expected completion of recruitment in 2025, and anticipates topline data in 2026
** The late-stage trial will test the efficacy and safety of avexitide in participants with PBH following gastric bypass surgery
** Up to last close, stock was down 63.7% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。